Universal reference book for medicines
Product name: ISOFRA (ISOFRA)

Active substance: framycetin

Type: Antibacterial preparation for topical application in ENT practice

Manufacturer: Laboratoires BOUCHARA-RECORDATI (France)
Composition, form of production and packaging
Spray nasal 1.25%
1 ml

framicetin sulfate 12.5 mg (8 thousand IU)

Auxiliary substances: methylparahydroxybenzoate, sodium chloride, citric acid, distilled water.

15 ml - polyethylene bottles (1) complete with a spray - packs cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2012.

PHARMACHOLOGIC EFFECT

Antibiotic from the group of aminoglycosides for topical application in otorhinolaryngology.
It is bactericidal. It is active against gram-positive and gram-negative bacteria that cause the development of infectious processes in the upper respiratory tract.
PHARMACOKINETICS

Studies of the pharmacokinetics of the preparation of Isophra have not been carried out due to low systemic absorption.

INDICATIONS

As part of combination therapy for infectious and inflammatory diseases of the upper respiratory tract, including:

- rhinitis;

- Rhinopharyngitis;

- sinusitis (in the absence of damage to the septum).

Preventive maintenance and treatment of inflammatory processes after surgical interventions.

DOSING MODE

Adults appoint 1 injection in each nostril 4-6 times / day.

Children are prescribed 1 injection each nostril 3 times / day.

The average duration of therapy is 7 days.

When using the bottle should be kept in a vertical position.

SIDE EFFECT

Allergic reactions: in single cases - skin manifestations.

CONTRAINDICATIONS

- Hypersensitivity to framicetin and other antibiotics from the group of aminoglycosides.

PREGNANCY AND LACTATION

Adequate and strictly controlled clinical trials of the safety of the use of Isofra during pregnancy and lactation (breastfeeding) were not carried out.

APPLICATION FOR CHILDREN

The application is possible according to the dosing regimen.

SPECIAL INSTRUCTIONS

If the therapeutic effect is absent or weakly expressed within 7 days of treatment, the drug must be discontinued.

OVERDOSE

Due to the low degree of absorption in the systemic blood flow, an overdose is unlikely.

DRUG INTERACTION

Clinically significant interactions of the preparation with other medicines have not been identified.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored at a temperature of no higher than 25 ° C.
Shelf life - 3 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!